INTRODUCTION
Chronic liver disease is a major global health problem. Chronic hepatitis C virus (HCV) infection, chronic hepatitis B virus (HBV) infection, alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the main causes of chronic liver disease. Most chronic liver diseases have a similar clinical course with a prolonged asymptomatic early phase during which liver damage progresses silently and variable late clinical presentation of decompensated cirrhosis. The disease prognosis is closely associated with the severity of liver fibrosis and the majority of adverse outcomes occur after the development of liver cirrhosis [1] . As a result, liver fibrosis severity is currently the most reliable patient prognostic measure. Additionally, the measurement of liver fibrosis can help to guide important clinical management decisions that include the need for treatment and the initiation of hepatocellular carcinoma and liver decompensation surveillance.
Histopathological staging of liver biopsy has been used as the gold standard for liver fibrosis measurement. However liver biopsy is limited in its use due to its invasive nature, sampling error and risk of serious complications or death [2] . Furthermore, liver biopsy is inconvenient, expensive and not widely accessible to a large number of patients or physicians. Surrogate serum fibrosis models that can accurately predict the severity of liver fibrosis are of great clinical significance. Compared to liver biopsy, serum fibrosis models have advantages of low cost, wide availability, high reproducibility and non-invasive nature. During the last two decades, a number of serum fibrosis models have been developed and a few of them have been well validated and used in routine clinical practice.
Hepascore is a serum model that was developed to predict the severity of liver fibrosis in patients with chronic hepatitis C [3] . Hepascore includes four biomarkers, namely: alpha2-macroglobulin, hyaluronic acid, bilirubin and gamma-glutamyl transpeptidase, as well as age and gender [3] . After the initial development and validation of Hepascore in chronic hepatitis
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This article is protected by copyright. All rights reserved. C, Hepascore has been more widely validated in chronic hepatitis B, ALD and NAFLD to detect significant liver fibrosis (Metavir F2, F3, F4), advanced fibrosis (Metavir F3, F4) and cirrhosis (Metavir F4). However, no meta-analysis of these studies has been performed. This study performed a meta-analysis of all Hepascore validation studies to evaluate the summary diagnostic performance of Hepascore and to compare it across different aetiologies of chronic liver disease.
MATERIALS AND METHODS

Literature search strategy
An electronic search was performed on PubMed and Cochrane library using the key word "Hepascore" from October 2005 to September 2015. Studies were included if they met the following inclusion criteria: 1) The whole population or a sub-group of patients who had chronic hepatitis C with or without HIV co-infection, chronic hepatitis B with or without HIV co-infection, ALD, NAFLD or mixed aetiology of chronic liver disease could be extracted from the study. 2) Both liver biopsy and Hepascore were performed for patients and the diagnostic performance of Hepascore was evaluated. 3) Studies provided the area under ROC curve (AUROC) (95% CI) of Hepascore for different fibrosis stages and/or the true positive, true negative, false positive and false negative of at least one cut point could be calculated from the data. Exclusion criterial included: 1) non-English literature. 2) reviews. 3) duplicated cohorts. 4) The target population were patients with liver disease other than chronic hepatitis C, chronic hepatitis B, ALD and NAFLD.
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Study inclusion and quality assessment
The studies were assessed by two independent reviewers using predetermined inclusion and exclusion criteria. The quality of each study was determined by using the validated quality assessment of diagnostic accuracy studies (QUADAS) questionnaire [4] . The questionnaire included 14 questions that covered use of appropriate patient population and reference standard, disease progression bias, verification bias, review bias, clinical review bias, incorporation bias, test execution, study withdrawals and indeterminate bias [4] . For each question, yes, no or unclear was scored. Disagreements between the two reviewers were resolved through further review.
Statistical analysis
Two approaches were used to evaluate the summary diagnostic performance of Hepascore.
Firstly, meta-analysis was performed using the random effects model for all included studies that provided both AUROC and 95% CI. Previous studies found that the AUROC was significantly influenced by the distribution of fibrosis stages [5] . Hence, the AUROC was standardized according to the difference between the mean fibrosis stages in advanced fibrosis and non-advanced fibrosis groups (DANA) using the formula: adAUROC = obAUROC + (0.1056) * (2.5 -DANA) [5] . Meta-analysis was performed for both observed AUROC (obAUROC) and adjusted AUROC (adAUROC). ObAUROC and adAUROC of Hepascore was compared between different aetiologies of chronic liver disease. Metaregression analysis and sensitivity analysis were used to evaluate the influence of seven characteristics of individual studies on AUROC, namely: patient inclusion methods (single centre vs multicentre), mean biopsy length (<20mm vs ≥20mm), biopsy evaluation (blinded vs not blinded), interval time between biopsy and serum collection (within one month vs >1
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Secondly, a summary ROC (SROC) model was calculated for all included studies from which at least one 2X2 table containing true positive, true negative, false positive and false negative could be created [6] . Summary sensitivity and specificity of validated cut points to predict significant fibrosis, advanced fibrosis and cirrhosis were calculated. The estimated positive predictive value (PPV) and negative predictive value (NPV) of each cut point was calculated using the observed prevalence.
RESULTS
Literature search results
A total of 55 articles were identified from the literature search. 45 were original studies and were published in English. 24 studies were excluded for the following reasons: 14 studies did not evaluate the diagnostic performance of Hepascore or did not provide sufficient data for the meta-analysis; six studies evaluated the utility of Hepascore in other types of liver disease; four studies had duplicated cohorts. 21 studies were included in the final analysis. The main characteristics of these studies were shown in table 1 [3, . A total of 5686 patients were included: 3523 had HCV infection, 441 had HCV/HIV co-infection, 588 had HBV infection, 108 had HBV/HIV co-infection, 321 had ALD, 242 had NAFLD and 463 had mixed aetiology of chronic liver disease. 11% patients had Metavir F0 (range: 0-44%), 34% had Metavir F1 (range: 11-47%), 25% had Metavir F2 (range 17-40%), 15% had Metavir F3 (range: 3-25%), 15% had Metavir F4 (range: 6-32%). According to the QUADAS
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for NAFLD and mixed aetiologies due to only one study of each cause was available for analysis.
The diagnostic performance of at least one cut point was reported in 18 cohorts and these were included in the SROC analysis (table 3) . The average prevalence of significant fibrosis was 52% (ranged: 41% -66%). The summary AUROC for all causes of liver disease was 0.79 (95%CI, 0.76-0.83) and this was similar to the AUROC calculated using the random effects model ( figure 2A ). The summary diagnostic odds ratio (DOR) was 7. 
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Sensitivity analysis
A sensitivity analysis was performed to test the effect of study characteristics on the adAUROC of Hepascore. No significant effect on adAUROC was found when patient inclusion methods, mean biopsy length, biopsy evaluation, interval time between biopsy and serum collection, timing of serum collection, hyaluronic acid test kit and study quality were analysed (table 4) .
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This article is protected by copyright. All rights reserved. Significant heterogeneity of obAUROC was found between all studies. This was heterogeneity was reduced but still remained significant after adjustment of the AUROC for DANA. This suggested that heterogeneity might be partly caused by the different distribution of fibrosis stages between studies. Subgroup analysis of disease aetiology found that heterogeneity of adAUROC was no longer significant within: HCV, HBV, HIV co-infection and ALD to predict significant fibrosis; in HIV co-infection to predict advanced fibrosis and in HCV, HBV, HIV co-infection to predict cirrhosis. This suggests that in addition to fibrosis distribution different aetiologies of chronic liver disease was another cause of heterogeneity between studies. Meta-regression analysis and sensitivity analysis was performed using seven pre-defined study characteristics. However, none of these characteristics showed a significant effect on AUROC. Others had previously found that blinded biopsy reviewing and histological staging system had an effect on the AUROC of other serum models [28] . The small number of studies that included in each subgroup made further analysis of the source of
heterogeneity impossible. Another limitation of this study was the potential bias that may have been a result of only including published full length articles to ensure adequate and comprehensive assessment of study quality.
In summary, this study confirmed that Hepascore is a useful measure of the severity of liver fibrosis in patients with the common causes of chronic liver disease. Hepascore had an excellent accuracy to exclude cirrhosis in all four causes of chronic liver disease and had good diagnostic performance for significant fibrosis and advanced fibrosis in chronic hepatitis C, chronic hepatitis B and alcoholic liver disease.
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